BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Dec 12, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

JX-594: Final Phase II data

Final data from 30 patients in the open-label, international Phase II HEP007 trial showed that low- and high-dose JX-594 administered 3 times at 2-week intervals led to a median overall survival (OS) of 6.7 and 13.8 months, respectively (p=0.029 for superiority of the high dose). Additionally, a greater proportion of patients receiving high-dose JX-594 were alive at 1 year vs....

Read the full 278 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >